MALE GENITAL SYSTEM - Pathology
MALE GENITAL SYSTEM - Pathology
MALE GENITAL SYSTEM - Pathology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>MALE</strong> <strong>GENITAL</strong> <strong>SYSTEM</strong><br />
• PENIS<br />
• SCROTUM, TESTIS, & EPIDIDYMIS<br />
• PROSTATE<br />
KUMAR, COTRAN, AND ROBBINS<br />
CH 18
PENIS<br />
• MALFORMATIONS<br />
• INFLAMMATORY LESIONS<br />
• NEOPLASMS
MALFORMATIONS OF THE PENIS<br />
ABNORMAL LOCATION OF URETHRAL ORIFICE<br />
ALONG PENILE SHAFT<br />
– HYPOSPADIAS (VENTRAL ASPECT)<br />
• MOST COMMON (1/300 LIVE <strong>MALE</strong> BIRTHS)<br />
– EPISPADIAS (DORSAL ASPECT)<br />
– MAY BE ASSOCIATED WITH OTHER <strong>GENITAL</strong><br />
ABNORMALITIES<br />
• INGUINAL HERNIAS<br />
• UNDESCENDED TESTES<br />
– CLINICAL CONSEQUENCES<br />
• CONSTRICTION OF ORIFICE<br />
• URINARY TRACT OBSTRUCTION<br />
• URINARY TRACT INFECTION<br />
• IMPAIRED REPRODUCTIVE FUNCTION
INFLAMMATORY LESIONS<br />
OF THE PENIS<br />
• SEXUALLY TRANSMITTED DISEASES<br />
• BALANITIS (BALANOPOSTHITIS)<br />
– INFLAMMATION OF THE GLANS (PLUS<br />
PREPUCE)<br />
– ASSOCIATED WITH POOR LOCAL<br />
HYGIENE IN UNCIRCUMCISED MEN<br />
• SMEGMA<br />
– DISTAL PENIS IS RED, SWOLLEN,<br />
TENDER<br />
• +/- PURULENT DISCHARGE
INFLAMMATORY LESIONS<br />
OF THE PENIS<br />
• PHIMOSIS<br />
– PREPUCE CANNOT BE EASILY<br />
RETRACTED OVER GLANS<br />
– MAY BE CON<strong>GENITAL</strong><br />
– USUALLY ASSOCIATED WITH<br />
BALANOPOSTHITIS AND<br />
SCARRING<br />
– PARAPHIMOSIS (TRAPPED GLANS)<br />
• URETHRAL CONSTRICTION
INFLAMMATORY LESIONS<br />
OF THE PENIS<br />
• FUNGAL INFECTIONS<br />
–CANDIDIASIS<br />
• ESPECIALLY IN DIABETICS<br />
• EROSIVE, PAINFUL, PRURITIC<br />
• CAN INVOLVE ENTIRE <strong>MALE</strong><br />
EXTERNAL <strong>GENITAL</strong>IA
NEOPLASMS OF THE PENIS<br />
• SQUAMOUS CELL CARCINOMA (SCC)<br />
– EPIDEMIOLOGY<br />
• UNCOMMON - ABOUT 1 % OF CA IN US MEN<br />
• UNCIRCUMCISED MEN BETWEEN 40 AND 70<br />
– PATHOGENESIS<br />
• POOR HYGIENE, SMEGMA<br />
• HUMAN PAPILLOMA VIRUS (16 AND 18)<br />
• CIS FIRST, THEN PROGRESSION TO<br />
INVASIVE SQUAMOUS CELL CARCINOMA
SCC OF THE PENIS<br />
• CLINICAL COURSE<br />
– USUALLY INDOLENT<br />
– LOCALLY INVASIVE<br />
– HAS SPREAD TO INGUINAL LYMPH NODES<br />
IN 25% OF CASES AT PRESENTATION<br />
– DISTANT METS RARE<br />
– 5 YR SURVIVAL<br />
• 70% WITHOUT LN METS<br />
• 27% WITH LN METS
LESIONS INVOLVING THE<br />
SCROTUM<br />
• INFLAMMATION<br />
– TINEA CRURIS (JOCK ITCH)<br />
• SUPERFICIAL DERMATOPHYTE INFECTION<br />
• SCALY, RED, ANNULAR PLAQUES, PRURITIC<br />
• INGUINAL CREASE TO UPPER THIGH<br />
• SQUAMOUS CELL CARCINOMA<br />
– HISTORICAL SIGNIFICANCE<br />
– SIR PERCIVAL POTT, 18TH CENTURY ENGLISH<br />
PHYSICIAN<br />
– CHIMNEY SWEEPS
LESIONS INVOLVING THE<br />
SCROTUM<br />
• SCROTAL ENLARGEMENT<br />
– HYDROCELE - MOST COMMON CAUSE<br />
• ACCUMULATION OF SEROUS FLUID WITHIN<br />
TUNICA VAGINALIS<br />
• INFECTIONS, TUMOR, IDIOPATHIC<br />
– HEMATOCELE<br />
– CHYLOCELE<br />
• FILIARIASIS - ELEPHANTIASIS<br />
– TESTICULAR DISEASE
LESIONS OF THE TESTES<br />
• CON<strong>GENITAL</strong><br />
• INFLAMMATORY<br />
• NEOPLASTIC
CRYPTORCHIDISM AND<br />
TESTICULAR ATROPHY<br />
• FAILURE OF TESTICULAR DESCENT<br />
• EPIDEMIOLOGY<br />
– ABOUT 1% OF <strong>MALE</strong>S<br />
– RIGHT > LEFT, 25% BILATERAL<br />
• PATHOGENESIS<br />
– HORMONAL ABNORMALITIES<br />
– TESTICULAR ABNORMALITIES<br />
– MECHANICAL PROBLEMS
CRYPTORCHIDISM AND<br />
TESTICULAR ATROPHY<br />
• CLINICAL COURSE<br />
– WHEN UNILATERAL, MAY SEE ATROPHY IN<br />
CONTRALATERAL TESTIS<br />
– STERILITY<br />
– INCREASED RISK OF MALIGNANCY (10X)<br />
– ORCHIOPEXY<br />
• MAY HELP PREVENT ATROPHY<br />
• DOES NOT DECREASE RISK OF MALIGNANCY
OTHER CAUSES OF<br />
TESTICULAR ATROPHY<br />
• CHRONIC ISCHEMIA<br />
• INFLAMMATION OR TRAUMA<br />
• HYPOPITUITARISM<br />
• EXCESS FE<strong>MALE</strong> SEX HORMONES<br />
– THERAPEUTIC ADMINISTRATION<br />
– CIRRHOSIS<br />
• MALNUTRITION<br />
• IRRADIATION<br />
• CHEMOTHERAPY
INFLAMMATORY LESIONS<br />
OF THE TESTIS<br />
• USUALLY INVOLVE THE EPIDIDYMIS<br />
FIRST<br />
• SEXUALLY TRANSMITTED DISEASES<br />
• NONSPECIFIC EPIDIDYMITIS AND<br />
ORCHITIS<br />
– SECONDARY TO UTI<br />
• BACTERIAL AND NON-BACTERIAL<br />
– SWELLING, TENDERNESS<br />
– ACUTE INFLAMMATORY INFILTRATE
INFLAMMATORY LESIONS OF<br />
THE TESTIS<br />
• MUMPS<br />
– 20% OF ADULT <strong>MALE</strong>S WITH MUMPS<br />
– EDEMA AND CONGESTION<br />
– CHRONIC INFLAMMATORY INFILTRATE<br />
– MAY CAUSE ATROPHY AND STERILITY<br />
• TUBERCULOSIS<br />
– GRANULOMATOUS INFLAMMATION<br />
– CASEOUS NECROSIS<br />
• AUTOIMMUNE GRANULOMATOUS<br />
ORCHITIS<br />
– RARE FINDING IN MIDDLE AGED MEN
TESTICULAR NEOPLASMS<br />
• EPIDEMIOLOGY<br />
– MOST IMPORTANT CAUSE OF PAINLESS<br />
ENLARGEMENT OF TESTIS<br />
– 6/100,000 <strong>MALE</strong>S, WHITES > BLACKS (US)<br />
– INCREASED FREQUENCY IN SIBLINGS<br />
– PEAK INCIDENCE 15-34 YRS<br />
– MOST ARE MALIGNANT<br />
– ASSOCIATED WITH GERM CELL<br />
MALDEVELOPMENT<br />
• CRYPTORCHIDISM<br />
• TESTICULAR DYSGENESIS(XXY)
TESTICULAR NEOPLASMS<br />
• PATHOGENESIS<br />
– 95% ARISE FROM GERM CELLS<br />
• ISOCHROMOSOME 12, i(12p), IS A COMMON<br />
FINDING<br />
– RARELY ARISE FROM SERTOLI CELLS<br />
OR LEYDIG CELLS<br />
• THESE ARE OFTEN BENIGN<br />
– Lymphoma<br />
• men > 60 yo
WHO CLASSIFICATION OF<br />
TESTICULAR TUMORS<br />
• ONE HISTOLOGIC PATTERN (40%)<br />
– SEMINOMAS (30%)<br />
– EMBRYONAL CARCINOMA<br />
– YOLK SAC TUMOR<br />
– CHORIOCARCINOMA<br />
– TERATOMA<br />
• MULTIPLE HISTOLOGIC PATTERNS (60%)<br />
– EMBRYONAL CA + TERATOMA<br />
– CHORIOCARCINOMA + OTHER<br />
– OTHER COMBINATIONS
HISTOGENESIS OF TESTICULAR<br />
NEOPLASMS (PEAK INCIDENCE)<br />
GERM CELL PRECURSOR<br />
GONADAL<br />
DIFFERENTIATION<br />
TOTIPOTENTIAL<br />
DIFFERENTIATION<br />
(NONSEMINOMA)<br />
SEMINOMA<br />
(40-50 Y)<br />
TROPHOBLASTIC<br />
DIFFERENTIATION<br />
EMBRYONAL CA<br />
(UNDIFFERENTIATED)<br />
(20-30 Y)<br />
YOLK SAC<br />
DIFF<br />
SOMATIC<br />
DIFFERENTIATION<br />
TERATOMA<br />
(20-30 Y)<br />
CHORIOCARCINOMA<br />
(20-30 Y)<br />
hCG +<br />
YOLK SAC TUMOR<br />
(< 3 Y)<br />
AFP +<br />
MATURE<br />
IMMATURE<br />
MALIGNANT TX
CLINICAL COURSE OF<br />
TESTICULAR TUMORS<br />
• USUALLY PRESENT WITH PAINLESS<br />
ENLARGEMENT OF TESTIS<br />
• MAY PRESENT WITH METASTASES<br />
– NONSEMINOMAS (MORE COMMON)<br />
• LYMPH NODES, LIVER AND LUNGS<br />
– SEMINOMAS<br />
• USUALLY JUST REGIONAL LYMPH NODES<br />
• TUMOR MARKERS (hCG AND AFP)<br />
• TREATMENT SUCCESS DEPENDS ON<br />
HISTOLOGY AND STAGE<br />
– SEMINOMAS VERY SENSITIVE TO BOTH<br />
RADIO- AND CHEMOTHERAPY
DISEASES OF THE<br />
PROSTATE<br />
• PROSTATITIS<br />
• NODULAR HYPERPLASIA<br />
• CANCER
PROSTATITIS<br />
• ACUTE BACTERIAL PROSTATITIS<br />
• CHRONIC BACTERIAL PROSTATITIS<br />
• CHRONIC ABACTERIAL PROSTATITIS
• ETIOLOGY<br />
ACUTE BACTERIAL<br />
PROSTATITIS<br />
– SAME ORGANISMS THAT CAUSE UTI<br />
• E coli, OTHER GNR<br />
• PATHOGENESIS<br />
– ORGANISMS ASCEND FROM URETHRA<br />
AND URINARY BLADDER<br />
– RARELY, HEMATOGENOUS SPREAD
ACUTE BACTERIAL<br />
PROSTATITIS<br />
• MORPHOLOGY<br />
– ACUTE INFLAMMATION, ESPECIALLY IN THE<br />
GLANDS, WITH MICROABSESSES<br />
– CONGESTION, EDEMA<br />
• CLINICAL COURSE<br />
– DYSURIA, FREQUENCY, LOW BACK PAIN,<br />
PELVIC PAIN<br />
– ENLARGED, EXQUISITELY TENDER<br />
– +/- FEVER OR LEUKOCYTOSIS<br />
– USUALLY RESOLVES WITH WITH AB RX
CHRONIC PROSTATITIS<br />
• ETIOLOGY<br />
– MAY FOLLOW ACUTE PROSTATITIS<br />
– MAY DEVELOP INSIDIOUSLY<br />
– CULTURE POSITIVE (BACTERIAL)<br />
• SAME ORGANISMS THAT CAUSE AP<br />
– CULTURE NEGATIVE (ABACTERIAL)<br />
• MAY BE RELATED TO<br />
– CHLAMYDIA TRACHOMATIS<br />
– UREAPLASMA UREALYTICUM<br />
• MOST COMMON FORM OF CP
CHRONIC PROSTATITIS<br />
• MORPHOLOGY<br />
– LYMPHOCYTIC INFILTRATE<br />
– NEUTROPHILS AND MACROPHAGES<br />
– SOME EVIDENCE OF TISSUE DESTRUCTION<br />
• CLINICAL COURSE<br />
– SIMILAR TO AP<br />
• LESS ACUTE SYMPTOMS<br />
• MORE RESISTANT TO AB RX<br />
– CBP OFTEN ASSOCIATED WITH RECURRENT<br />
UTI
PROLIFERATIVE LESIONS OF THE PROSTATE<br />
PERIURETHRAL<br />
AND<br />
TRANSITIONAL<br />
ZONES<br />
NORMAL PROSTATE<br />
URETHRA<br />
PERIPHERAL<br />
ZONE<br />
NODULAR HYPERPLASIA<br />
CARCINOMA
NODULAR HYPERPLASIA<br />
• OTHER TERMS USED<br />
– GLANDULAR AND STROMAL<br />
HYPERPLASIA<br />
– BENIGN PROSTATIC HYPERTROPHY<br />
(HYPERPLASIA)<br />
• EPIDEMIOLOGY<br />
– OCCURS IN 20% OF MEN OVER 40<br />
– OCCURS IN 90% OF MEN OVER 70
PATHOGENESIS OF<br />
NODULAR HYPERPLASIA<br />
• PROLIFERATION OF BOTH EPITHELIAL<br />
AND STROMAL ELEMENTS<br />
• BOTH ANDROGENS AND ESTROGENS MAY<br />
PLAY A ROLE<br />
– NOT SEEN IN <strong>MALE</strong>S CASTRATED BEFORE<br />
PUBERTY<br />
– INHIBITORS OF TESTOSTERONE METABOLISM<br />
USEFUL IN TREATMENT<br />
– RELATIVE INCREASE IN ESTROGENS IN OLDER<br />
MEN MAY INCREASE DHT RECEPTORS IN<br />
PROSTATE
CLINICAL COURSE OF<br />
NODULAR HYPERPLASIA<br />
• SYMPTOMS OCCUR IN ONLY 10% OF MEN<br />
WITH NODULAR HYPERPLASIA<br />
• HESITANCY<br />
• URINARY RETENTION<br />
– URGENCY, FREQUENCY, NOCTURIA, UTI<br />
• TREATMENT<br />
– MEDICAL<br />
– SURGICAL<br />
• COMMON CAUSE FOR ELEVATED<br />
PROSTATE SPECIFIC ANTIGEN (PSA)
CARCINOMA OF THE<br />
PROSTATE<br />
• EPIDEMIOLOGY<br />
– MOST COMMON VISCERAL CANCER<br />
• ABOUT 70/100,000 MEN IN US<br />
• 200,000 NEW CASES/YR IN US<br />
• 20% ARE LETHAL<br />
– SECOND MOST COMMON CAUSE OF CANCER<br />
DEATH IN MEN<br />
– PEAK INCIDENCE OF CLINICAL CANCER IS 65-<br />
75 YO<br />
– LATENT CA IS EVEN MORE PREVALENT<br />
• >50% IN MEN > 80 YO
CARCINOMA OF THE<br />
PROSTATE<br />
• PATHOGENESIS<br />
– HORMONAL FACTORS<br />
• DOES NOT OCCUR IN EUNUCHS<br />
• ORCHIECTOMY AND/OR ESTROGEN TREATMENT<br />
INHIBITS GROWTH<br />
– GENETIC FACTORS<br />
• INCREASED RISK IN FIRST ORDER RELATIVES<br />
• BLACKS > WHITES (SYMPTOMATIC CA)<br />
– ENVIRONMENTAL FACTORS<br />
• GEOGRAPHIC DIFFERENCES IN INCIDENCE OF<br />
CLINICAL CANCER (NOT OF LATENT CA)<br />
• CHANGE IN INCIDENCE WITH MIGRATION
CARCINOMA OF THE PROSTATE<br />
• CLINICAL COURSE<br />
– OFTEN CLINICALLY SILENT<br />
– DIGITAL RECTAL EXAM (DRE)<br />
– PROSTATE SPECIFIC ANTIGEN (PSA)<br />
• > 4 ng/ml IN PERIPHERAL BLOOD<br />
• FREE PSA < 25%<br />
– TRANSRECTAL ULTRASOUND<br />
– NEEDLE BIOPSY<br />
– PROSTATISM (LIKE BPH)<br />
– METASTASES<br />
• OSTEOBLASTIC<br />
– TREATMENT- SURGERY, RADIATION,<br />
HORMONES, CHEMO
• STAGING<br />
A<br />
B<br />
C<br />
D<br />
CARCINOMA OF THE<br />
MICROSCOPIC ONLY<br />
MACROSCOPIC (PALPABLE)<br />
EXTRACAPSULAR<br />
METASTATIC<br />
PROSTATE<br />
• PROGNOSIS DEPENDENT ON STAGE AND<br />
HISTOLOGIC GRADE<br />
– 90% 10 YR SURVIVAL FOR A AND B<br />
– 10-40% 10 YR SURVIVAL FOR C AND D